Skip to search formSkip to main contentSkip to account menu

liarozole

An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (5)

Androgen AntagonistsAntineoplastic Agents, HormonalDermatologic AgentsEnzyme Inhibitors
Liarozole HydrochlorideNCIt Antineoplastic Agent Terminologyliarozole fumarate

Narrower (3)

LiazalR 085246R 75251

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Combined use of ionic liquid and hydroxypropyl-β-cyclodextrin for the enantioseparation of ten drugs by capillary electrophoresis.
In the present study, hydroxypropyl-β-cyclodextrin and an ionic liquid (1-ethyl-3-methylimidazolium-l-lactate) were used as… 
2009
2009
Expression of retinoid-regulated genes in lamellar ichthyosis vs. healthy control epidermis: changes after oral treatment with liarozole.
Lamellar ichthyosis is a keratinization disorder caused by TGM1, Ichthyin and several other gene mutations. A new treatment… 
2002
2002
Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl…
The remarkable toxicity of (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid (TTNPB… 
2000
2000
Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
Liarozole is a 1-substituted imidazole derivative that inhibits cytochrome P450 activity and increases endogenous plasma… 
Highly Cited
1998
Highly Cited
1998
The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
The imidazole derivative liarozole is a potent inhibitor of cytochrome P450‐dependent 4‐hydroxyla‐tion of endogenous all‐trans… 
1998
1998
Novel nonsteroidal inhibitor of cytochrome P45017α (17α‐hydroxylase/C17–20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats
The purpose of this study was to determine the effects of a nonsteroidal C17–20 lyase inhibitor, 2‐(1H‐imidazol‐4‐ylmethyl)‐9H… 
1996
1996
Enhancement of antiproliferative activity of 1α,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific
1996
1996
Liarozole amplifies retinoid‐induced apoptosis in human prostate cancer cells
Beta-carotene, canthaxanthin and retinoic acid (RA) inhibited growth of human DU145 prostate cancer cells by 45, 56 and 18… 
1995
1995
Liarozole, an antitumor drug, modulates cytokeratin expression in the dunning AT‐6sq prostatic carcinoma through in situ accumulation of all‐trans‐retinoic acid
Liarozole showed antitumoral activity in the Dunning AT‐6sq, an androgen‐independent rat prostate carcinoma. To investigate its… 
1993
1993
Oral Liarozole as a Catabolic Inhibitor Potently Increases Retinoic Acid in vivo: First Experience from an Ongoing Therapeutic Trial in Highly Malignant Primary Brain Tumors
Background: Retinoic acid, the intracellular metabolite of vitamin A, induces differentiation in glioblastoma cultures and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)